this knowledge to identify new therapeutic targets. The company develops inhibitors designed to alter RNA-modifying enzymes, which play a role in regulating gene expression and disease progression. Its lead candidate, STC-15, is an inhibitor of the RNA-modifying enzyme METTL3 and is being evaluated in clinical studies for various cancers. In addition to oncology, the company’s platform is applied to other conditions such as inflammation, viral infections, and central nervous system disorders, reflecting a broader focus on RNA biology–based therapeutics.